bluebird bio - BLUE Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

11 brokerages have issued 1-year price objectives for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $14.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $9.99 at the beginning of 2022. Since then, BLUE stock has decreased by 24.5% and is now trading at $7.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.31) by $0.02. The biotechnology company earned $1.52 million during the quarter, compared to analysts' expectations of $6.47 million. bluebird bio had a negative net margin of 2,141.34% and a negative trailing twelve-month return on equity of 130.19%.

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $7.54.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $581.50 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($8.32) on an earnings per share basis.

The company employs 518 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.